Arthneeti
All Q3 FY25 results →
C

Cipla Ltd

Q3 FY25Pharmaceuticals & Biotechnology

Cipla Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹1,432
Market cap₹1.2L Cr
P/E32.7
Updated23 Aug 2026
Read4 min read

The short version

FY'26 revenue growth is expected, supported by launches of Advair and Abraxane in H2 FY'26 and partnered inhalation assets (Page 6, 7, 8). Cipla expects top-line growth to continue in FY26, with detailed profitability guidance pending budget finalization.

From Cipla Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY'26 revenue growth is expected, supported by launches of Advair and Abraxane in H2 FY'26 and partnered inhalation assets (Page 6, 7, 8).
  • Pipeline includes notable respiratory assets and peptides aimed for launch in 18-24 months (Page 8).
  • One India business aims to continue growth momentum ahead of market at 10% YoY with expansion in branded prescription and trade generics segments (Page 6, 7).
  • One Africa and EMEU combined delivered 15% YoY INR growth, supporting diversified and resilient business model (Page 4).
  • Respiratory portfolio expected to grow significantly with launch of generic Advair, Symbicort, and other inhalation assets, increasing respiratory share in the US market over time (Page 12).

2 more points from Cipla Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Cipla Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Cipla has invested nearly $100 million CAPEX in US facilities between FY'20 and FY'25 to enhance DPI, MDI, and large volume OSD manufacturing.
  • The company continues to invest strategically in India, branded prescription business, especially chronic therapies, adding 1,800+ field force employees since FY'23.
  • A retail task force of 500+ has been added in India to improve business visibility.
  • Cipla retains a guidance of 5% to 6% of revenue in R&D investment to add more product programs despite moderating clinical trial costs.

2 more points from Cipla Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Cipla Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Cipla. However, relevant information includes: - Cipla has a strong launch pipeline that supports business resilience and growth (Page 4). - The company expects significant product launches in the US like Advair, Abraxane, Symbicort (launch expected in the second half of FY'27), and other respiratory and peptide assets within 18-24 months (Pages 8, 12, 18). - Supply issues with Lanreotide are expected to be resolved by end of March with capacity ramp-up underway (Pages 9, 12).

2 more points from Cipla Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Cipla Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹6.5K Cr, net profit ₹543 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Cipla's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cipla Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cipla Ltd Q3 FY25 results?

FY'26 revenue growth is expected, supported by launches of Advair and Abraxane in H2 FY'26 and partnered inhalation assets (Page 6, 7, 8). Cipla expects top-line growth to continue in FY26, with detailed profitability guidance pending budget finalization.

What is Cipla Ltd share price analysis?

Cipla Ltd currently shows a neutral. The stock trades at a P/E of 32.7 with a market cap of ₹117,139 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cipla Ltd planning capital expenditure?

Cipla has invested nearly $100 million CAPEX in US facilities between FY'20 and FY'25 to enhance DPI, MDI, and large volume OSD manufacturing.

Keep Cipla Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.